Cheryl Koehn of ACE, and the Canadian Digestive Health Foundation first
annual winners for work on behalf of patients
OTTAWA, Sept. 25 /CNW/ - Cheryl Koehn, a volunteer with Arthritis
Consumer Experts, and the Canadian Digestive Health Foundation, a national
patient organization working to raise awareness of the needs of patients with
digestive diseases such as Inflammatory Bowel Disease, were the first two
recipients of the BIOTECanada-UCB Pharma Health Innovation Patient Advocacy
Awards, presented today in Toronto.
The awards were presented at the Biotechnology Initiative/BIOFinance
Leadership Luncheon in front of industry leaders and guest speaker, the
honourable Peter Beattie, Trade and Investment Commissioner for the Americas
and former Premier of Queensland, Australia. The awards are designed to
recognize an individual and a non-profit organization that have made
outstanding contributions to the healthcare system through their work to
inform Canadians, empower patients, and advocate for innovative solutions in
"As the face of health care policy changes, patient groups and volunteers
are on the front lines, making a difference in our health care system
everyday," said Peter Brenders, President and CEO, BIOTECanada. "All 20
nominees have shown exceptional dedication in bringing to the forefront the
challenges of Canadians living with debilitating conditions, and I am proud to
celebrate their contributions."
"Through our business, we work closely with various patient groups
everyday and see the important contribution they are making to Canadians'
lives," said Rob Hamilton, President and General Manager, UCB Pharma Canada.
"One of our core company values at UCB is putting patients at the centre of
everything we do. These awards are dedicated to recognizing leaders in health
policy and patient advocacy who are making a real difference in the lives of
Canadians living with difficult diseases. We are proud to partner with
BIOTECanada on these awards."
The individual winner receives a $5,000 prize, and the non-profit
organization winner receives $10,000. Winners were chosen on the basis of
their impact on public awareness of diseases; their contribution to generating
public healthcare policy change; demonstrated leadership, creativity an
innovative thinking; an effective program of action, and realizing a better
health care environment for Canadians. The Awards were judged by an
independent panel of medical practitioners and healthcare policy experts.
ABOUT BIOTECanada www.biotech.ca
BIOTECanada is dedicated to the sustainable commercial development of
biotechnology innovation in Canada. It is the national industry-funded
association with over 230 members representing the broad spectrum of biotech
constituents including emerging and established companies in the health,
industrial, and agricultural sectors, as well as academic and research
institutions and other related organizations.
ABOUT UCB PHARMA CANADA
UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the
biopharmaceutical industry dedicated to the research, development and
commercialisation of innovative pharmaceutical and biotechnology products in
the fields of central nervous system disorders, allergy/respiratory diseases,
immune and inflammatory disorders and oncology. UCB focuses on securing a
leading position in severe disease categories.
UCB Pharma Canada was officially incorporated in 2006 with the objective
of bringing new and convenient therapies to the Canadian market for
auto-immune, inflammatory diseases and central nervous system disorders. As a
patient-focused organization, UCB Pharma Canada is dedicated to bringing new
and innovative programs to patients, and to the specialists who treat them, to
help improve the lives of people living with severe diseases.
For further information:
For further information: Kasia Majewski, Director of Communications,
BIOTECanada, (613) 230-5585 x 257, cell: (613) 219-2770,
firstname.lastname@example.org; OR Chrome Communications, (905) 567-1406, Alon
Barmapov, ext. 223; (647) 405-1352, Ashley Jennison, ext. 222